ALNY vs MRK
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
ALNY's Piotroski F-Score of 4/9 indicates weak financial health, falling into the 'Weak' range, which raises concerns despite strong profitability and growth metrics. The company trades at a premium valuation with a P/E of 135.09 and Price/Sales of 11.19, significantly above sector averages, suggesting high growth expectations are already priced in. Insider selling activity totaling $11.62M over six months signals bearish sentiment from within the company, particularly from senior officers. While revenue growth is impressive at 84.9% YoY and ROE is exceptionally high at 73.28%, the lack of earnings consistency and negative free cash flow (implied by missing data) undermine sustainability. The Graham Number of $17.64 and intrinsic value of $16.24 are far below the current price of $313.41, indicating severe overvaluation unless future growth materializes at extraordinary rates.
MRK shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
ALNY vs MRK: Head-to-Head Comparison
This page compares Alnylam Pharmaceuticals, Inc. (ALNY) and Merck & Co., Inc. (MRK) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.